Using the PARPi (olaparib) or the CHK1 inhibitor (prexasertib) in combination with anti-PD-L1, a significant increase in cytotoxic T-cell infiltration inducing tumor regression was observed in the SCLC mouse model (79). This evidence concerns the gene CHEK1 and small cell lung carcinoma.